Cellectis SA (CLLS) Expected to Post FY2023 Earnings of $3.68 Per Share

Share on StockTwits

Cellectis SA (NASDAQ:CLLS) – Investment analysts at Oppenheimer issued their FY2023 earnings estimates for shares of Cellectis in a research note issued to investors on Tuesday, March 12th. Oppenheimer analyst H. Singh anticipates that the biotechnology company will post earnings per share of $3.68 for the year. Oppenheimer currently has a “Buy” rating and a $44.00 target price on the stock.

CLLS has been the subject of a number of other research reports. Goldman Sachs Group initiated coverage on Cellectis in a research report on Wednesday, December 19th. They issued a “neutral” rating and a $25.00 price target for the company. ValuEngine cut Cellectis from a “buy” rating to a “hold” rating in a research report on Friday, November 16th. BidaskClub cut Cellectis from a “sell” rating to a “strong sell” rating in a research report on Wednesday, November 21st. Zacks Investment Research upgraded Cellectis from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a research report on Thursday, January 3rd. Finally, Barclays reiterated a “buy” rating and set a $50.00 price objective on shares of Cellectis in a research report on Wednesday. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $32.00.

Shares of CLLS stock opened at $19.02 on Friday. Cellectis has a fifty-two week low of $15.34 and a fifty-two week high of $38.85. The firm has a market capitalization of $792.48 million, a PE ratio of -9.85 and a beta of 1.76.

A number of institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. boosted its stake in Cellectis by 24,158.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 48,517 shares of the biotechnology company’s stock worth $1,370,000 after buying an additional 48,317 shares during the last quarter. Altshuler Shaham Ltd acquired a new stake in Cellectis in the 3rd quarter worth about $1,120,000. Financial Gravity Companies Inc. acquired a new stake in Cellectis in the 4th quarter worth about $71,000. Point72 Asset Management L.P. boosted its stake in Cellectis by 118.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 156,133 shares of the biotechnology company’s stock worth $4,406,000 after buying an additional 84,533 shares during the last quarter. Finally, Macquarie Group Ltd. acquired a new stake in Cellectis in the 3rd quarter worth about $5,390,000. Hedge funds and other institutional investors own 27.62% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).

Read More: How to Use a Moving Average for TradingĀ 

Earnings History and Estimates for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

First Interstate Bancsystem  Cut to “Sell” at BidaskClub
First Interstate Bancsystem Cut to “Sell” at BidaskClub
Merchants Bancorp  Rating Lowered to Sell at ValuEngine
Merchants Bancorp Rating Lowered to Sell at ValuEngine
Head to Head Contrast: US Well Services  & Its Competitors
Head to Head Contrast: US Well Services & Its Competitors
Mid-America Apartment Communities  PT Raised to $120.00 at Royal Bank of Canada
Mid-America Apartment Communities PT Raised to $120.00 at Royal Bank of Canada
Brokerages Expect Stepan  Will Announce Earnings of $1.37 Per Share
Brokerages Expect Stepan Will Announce Earnings of $1.37 Per Share
Immersion  Upgraded by Zacks Investment Research to “Buy”
Immersion Upgraded by Zacks Investment Research to “Buy”


© 2006-2019 Ticker Report